Biomarker: F045-IgE Yeast

Overview

F045-IgE Yeast is a blood test that measures immunoglobulin E (IgE) antibodies directed against yeast allergens, generally associated with baker’s or brewer’s yeast (Saccharomyces cerevisiae). IgE is involved in immediate hypersensitivity reactions and can contribute to symptoms such as allergic rhinitis, asthma, hives, or, less commonly, food-related reactions. A high result indicates sensitization to the tested yeast extract, but it does not establish clinical allergy or predict reaction severity. The test is clinically useful when interpreted with exposure history and symptoms, particularly in suspected occupational respiratory allergy or reactions associated with yeast-containing foods or beverages.

Clinical Use Cases

Evaluation of suspected IgE-mediated sensitization to baker’s or brewer’s yeast.
Assessment of respiratory symptoms associated with occupational exposure to yeast-containing flour or bakery products.
Investigation of suspected allergic reactions after exposure to yeast-containing foods or beverages.
Supporting evaluation of allergic rhinitis, asthma, urticaria, or other immediate hypersensitivity symptoms when yeast exposure is clinically relevant.
Complementary testing when skin testing is unsuitable because of skin disease, medication use, or risk of a severe reaction.
Research into IgE-binding yeast allergens and possible cross-reactivity with other fungi, including Candida albicans.

Specimen Types

Venous whole blood, from which serum or plasma is analyzed.
Serum is the typical specimen for allergen-specific IgE measurement.

Measurement Methods

Fluorescence enzyme immunoassay or other automated allergen-specific IgE immunoassays.
Enzyme-linked immunosorbent assay, or ELISA.
Radioallergosorbent testing, or RAST, an older method.
Immunoblotting for research characterization of IgE-binding yeast proteins.

Test Preparation and Influencing Factors

Fasting is generally not required for an allergen-specific IgE blood test.
Patients should report antihistamines and other medications to the ordering clinician. Medications should not be stopped unless specifically instructed.
The result should be interpreted with the patient’s symptoms, timing of exposure, and exposure route.
A positive result indicates sensitization and does not by itself confirm symptomatic allergy.
The measured IgE concentration does not reliably predict the severity of a future reaction.
Cross-reactivity with other fungal allergens may contribute to positive results.
Total IgE, smoking, parasitic infection, age, and other clinical factors may influence interpretation of allergy testing.
Laboratory reporting units, thresholds, and class categories may differ between assay systems.